Sugi Predict

Sugi Predict / Compounds / SCHEMBL357299

SCHEMBL357299

SCHEMBL357299

CN(CCO)C(=O)c1ccc(Nc2ncnc3c2c(F)cn3C2CCN(c3ncc(Cl)cn3)CC2)c(F)c1

nearest known ligand 0.40

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
▸ GPR119 Q8TDV5 5/20 0.40
▸ ERBB2 P04626 2/20 0.38
▸ MKNK1 Q9BUB5 2/20 0.36
▸ CYP3A4 P08684 1/20 0.35
▸ CYP2C9 P11712 1/20 0.35
▸ CCNT1 O60563 1/20 0.35
▸ CDK4 P11802 1/20 0.35
▸ CCND3 P30281 1/20 0.35
▸ CDK9 P50750 1/20 0.35
▸ BRAF P15056 3/20 0.35
▸ WDR5 P61964 1/20 0.34
▸ KMT2A Q03164 1/20 0.34
▸ CDK1 P06493 1/20 0.34
▸ CDK2 P24941 1/20 0.34
▸ MKNK2 Q9HBH9 2/20 0.33
▸ EGFR P00533 1/20 0.33
▸ MAPT P10636 1/20 0.33
▸ NEK7 Q8TDX7 1/20 0.33
▸ LIMK1 P53667 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL10172628 0.96 GPR119 (0.39) GPR119ERBB2MKNK1CYP3A4CYP2C9
SCHEMBL10172692 0.94 GPR119 (0.41) GPR119ERBB2MKNK1CYP3A4CYP2C9
SCHEMBL10171912 0.94 GPR119 (0.41) GPR119ERBB2MKNK1CYP3A4CYP2C9
SCHEMBL354649 0.93 GPR119 (0.40) GPR119ERBB2MKNK1CYP3A4CYP2C9
SCHEMBL357883 0.92 GPR119 (0.44) GPR119ERBB2CYP3A4CYP2C9CCNT1
SCHEMBL10172693 0.92 GPR119 (0.41) GPR119ERBB2CYP3A4CYP2C9CCNT1
SCHEMBL357075 0.92 GPR119 (0.39) GPR119ERBB2MKNK1CYP3A4CYP2C9
SCHEMBL10172615 0.91 GPR119 (0.46) GPR119ERBB2MKNK1CYP3A4CYP2C9
SCHEMBL10171879 0.91 GPR119 (0.51) GPR119ERBB2MKNK1CYP3A4CYP2C9
SCHEMBL10172678 0.90 ERBB2 (0.40) GPR119ERBB2CYP3A4CYP2C9CCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US claimed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 — — EP claimed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 — — US claimed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US disclosed
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND MITSUBISHI TANABE PHARMA CORPORATION (JP) 2012-01-19 — — US disclosed
EP-2390254-A1 NOVEL PYRROLOÝ2,3-d¨PYRIMIDINE COMPOUND Mitsubishi Tanabe Pharma Corporation (JP) 2011-11-30 — — EP disclosed
US-20110257678-A1 VASCULAR EMBOLIC FILTER EXCHANGE DEVICES AND METHODS OF USE THEREOF INCEPT LLC (US) 2011-10-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120016119-A1 NOVEL PYRROLO(2,3-d)PYRIMIDINE COMPOUND GPR119, GPR139, HCAR1 GPR119 1/4885ERBB2 451/4885MKNK1 4806/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.